Objective To explore the long-term prognosis of anti-vascular endothelial growth factor (VEGF) drug for the treatment of patients with wet age-related macular degeneration (wAMD) and its influencing factors. MethodsThe clinical data of 56 patients (65 eyes) with wAMD who received intravitreal injection of anti-VEGF drug (conbercept) were retrospectively analyzed. All patients were followed up for 2 years, according to the improvement of naked eye visual acuity in patients, patients were divided into effective group or ineffective group. The clinical data were compared between patients of the two groups. The factors affecting patients′ long-term visual acuity were analyzed by the multivariate Logistic regression model. ResultsAmong 56 wAMD patients (65 eyes), the visual acuity of 32 cases (34 eyes) of patients (57.14%) was improved as compared with before treatment. There were statistically significant differences in disease course, the Self-Rating Scale of Sleep (SRSS) score after 1 day of treatment, and proportions of concomitant hypertension, concomitant coronary heart disease, as well as smoking history between the two groups (P＜0.05). The results of multivariate Logistic regression analysis revealed that disease course, SRSS score after 1 day of treatment, and concomitant hypertension were the influencing factors for long-term visual acuity of wAMD patients after anti-VEGF drug therapy (P＜0.05). ConclusionAnti-VEGF drug therapy can ameliorate long-term visual acuity of wAMD patients to a certain extent. Disease course, SRSS score after 1 day of treatment, and concomitant hypertension are the influencing factors for long-term visual acuity of wAMD patients after anti-VEGF drug therapy.

无